Systematic comparison of methods for determining the in vivo biodistribution of porous nanostructured injectable inorganic particles
Source abstract
Abstract
With a wide variety of biodistribution measurement techniques reported in the literature, it is important to perform side-by-side comparisons of results obtained with different methods on the same particle platform, to determine differences across methods, highlight advantages and disadvantages, and inform methods selection according to specific applications. Inorganic nanostructured particles (INPs) have gained a central role in the development of injectable delivery vectors thanks to their controllable design, biocompatibility, and favorable degradation kinetic. Thus, accurate determination of in vivo biodistribution of INPs is a key aspect of developing and optimizing this class of delivery vectors. In this study, a systematic comparison of spectroscopy (inductively coupled plasma optical emission spectroscopy), fluorescence (in vivo imaging system, confocal microscopy, and plate reader), and radiolabeling (gamma counter)-based techniques is performed to assess the accuracy and sensitivity of biodistribution measurements in mice. Each method is evaluated on porous silicon particles, an established and versatile injectable delivery platform. Biodistribution is evaluated in all major organs and compared in terms of absolute results (%ID/g and %ID/organ when possible) and sensitivity (σ%). Finally, we discuss how these results can be extended to inform method selection for other platforms and specific applications, with an outlook to potential benefit for pre-clinical and clinical studies. Overall, this study presents a new practical guide for selection of in vivo biodistribution methods that yield quantitative results. STATEMENT OF SIGNIFICANCE: The significance of this work lies in the use of a single platform to test performances of different biodistribution methods in vivo, with a strict quantitative metric. These results, united with the qualitative comparison of advantages and disadvantages of each technique, are aimed at supporting the rational choice of each different method according to the specific application, to improve the quantitative description of biodistribution results that will be published by others in the future.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Bone Tissue Engineering Materials · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (61)
Show source-provided references
1. Porous inorganic carriers based on silica, calcium carbonate and calcium phosphate for controlled/modulated drug delivery: fresh outlook and future perspectives10.3390/pharmaceutics10040167 ↗
2. Porous silicon advances in drug delivery and immunotherapy10.1016/j.coph.2013.06.006 ↗
3. In vivo evaluation of safety of nanoporous silicon carriers following single and multiple dose intravenous administrations in mice10.1016/j.ijpharm.2010.09.015 ↗
4. The mechanisms of surface chemistry effects of mesoporous silicon nanoparticles on immunotoxicity and biocompatibility10.1016/j.biomaterials.2013.06.052 ↗
5. Mechanism of erosion of nanostructured porous silicon drug carriers in neoplastic tissues10.1038/ncomms7208 ↗
6. Analysis of nanoparticle delivery to tumours10.1038/natrevmats.2016.14 ↗
7. Mechanism of hard-nanomaterial clearance by the liver10.1038/nmat4718 ↗
8. Establishing the effects of mesoporous silica nanoparticle properties on in vivo disposition using imaging-based pharmacokinetics10.1038/s41467-018-06730-z ↗
9. Advantages and limitations of current techniques for analyzing the biodistribution of nanoparticles10.3389/fphar.2018.00802 ↗
10. Noninvasive imaging of nanomedicines and nanotheranostics: principles, progress, and prospects10.1021/cr500314d ↗
11. Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution10.1016/j.jconrel.2011.10.021 ↗
12. Multistage mesoporous silicon-based nanocarriers: biocompatibility with immune cells and controlled degradation in physiological fluids
13. Discoidal porous silicon particles: fabrication and biodistribution in breast cancer bearing mice10.1002/adfm.201200869 ↗
14. Toxicological assessment of nano and micron-sized tungsten oxide after 28 days repeated oral administration to Wistar rats10.1016/j.mrgentox.2017.05.003 ↗
15. Biodistribution, clearance, and toxicology of polymeric micelles loaded with 0.9 or 5 nm gold nanoparticles10.1166/jbn.2015.2142 ↗
16. Sustained small interfering RNA delivery by mesoporous silicon particles10.1158/0008-5472.CAN-09-3931 ↗
17. In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles10.1016/j.jconrel.2013.10.016 ↗
18. Cancer optical imaging using fluorescent nanoparticles10.2217/nnm.10.144 ↗
19. Biodistribution studies of nanoparticles using fluorescence imaging: a qualitative or quantitative method?10.1007/s11095-012-0818-1 ↗
20. Near infrared fluorescence imaging in nano-therapeutics and photo-thermal evaluation
21. Rapid pharmacokinetic and biodistribution studies using cholorotoxin-conjugated iron oxide nanoparticles: a novel non-radioactive method10.1371/annotation/fe02e23b-5168-4586-ba49-d0e0286f4ad3 ↗
22. Multispectral optoacoustic tomography (MSOT) for imaging the particle size-dependent intratumoral distribution of polymeric micelles10.2147/IJN.S185726 ↗
23. Use of submicron vaterite particles serves as an effective delivery vehicle to the respiratory portion of the lung10.3389/fphar.2018.00559 ↗
24. Pharmacokinetics and biodistribution of polymeric micelles containing miRNA and small-molecule drug in orthotopic pancreatic tumor-bearing mice10.7150/thno.24945 ↗
25. Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery10.1016/j.jconrel.2013.06.039 ↗
26. Immune response and innervation signatures in aseptic hip implant loosening10.1186/s12967-016-0950-5 ↗
27. Near infrared fluorescence imaging of EGFR expression in vivo using IRDye800CW-nimotuzumab10.18632/oncotarget.23557 ↗
28. A novel method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies10.1186/2191-219X-2-50 ↗
29. A chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery10.1038/s41598-017-14221-2 ↗
30. Tailored porous silicon microparticles: fabrication and properties10.1002/cphc.200900914 ↗
31. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications10.1038/nnano.2008.34 ↗
32. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats10.2217/17435889.3.5.703 ↗
33. Principles of nanoparticle design for overcoming biological barriers to drug delivery10.1038/nbt.3330 ↗
34. Post-nano strategies for drug delivery: multistage porous silicon microvectors10.1039/C6TB01978A ↗
35. Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics10.1021/ar200077p ↗
36. Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation10.1002/jbm.a.32807 ↗
37. An injectable nanoparticle generator enhances delivery of cancer therapeutics10.1038/nbt.3506 ↗
38. Porous silicon microparticles for delivery of siRNA therapeutics
39. Investigation of parameters that determine Nano-DC vaccine transport10.1007/s10544-019-0397-6 ↗
40. Multistage vector (MSV) therapeutics10.1016/j.jconrel.2015.08.010 ↗
41. Cooperative, nanoparticle-enabled thermal therapy of breast cancer10.1002/adhm.201100005 ↗
42. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery10.1158/1078-0432.CCR-12-2764 ↗
43. Degradation and biocompatibility of multistage nanovectors in physiological systems10.1002/jbm.a.35017 ↗
44. High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics10.1021/nn4035316 ↗
45. Bone marrow endothelium-targeted therapeutics for metastatic breast cancer10.1016/j.jconrel.2014.04.057 ↗
46. Transport barriers and oncophysics in cancer treatment10.1016/j.trecan.2018.02.008 ↗
47. Discoidal porous silicon particles: fabrication and biodistribution in breast cancer bearing mice
48. Cell source determines the immunological impact of biomimetic nanoparticles10.1016/j.biomaterials.2015.11.054 ↗
49. Beating the Abbe diffraction limit in confocal microscopy via nonclassical photon statistics10.1103/PhysRevLett.113.143602 ↗
50. Haemoglobin interferes with the ex vivo luciferase luminescence assay: consequence for detection of luciferase reporter gene expression in vivo10.1038/sj.gt.3301248 ↗
51. Alternating block copolymer-based nanoparticles as tools to modulate the loading of multiple chemotherapeutics and imaging probes10.1016/j.actbio.2018.09.021 ↗
52. Ultra-small dye-doped silica nanoparticles via modified sol-gel technique10.1007/s11051-018-4227-1 ↗
53. Non-invasive in vivo imaging in small animal research
54. Advantages and limitations of current imaging techniques for characterizing liposome morphology10.3389/fphar.2018.00080 ↗
55. Endolysosomal proteolysis and its regulation10.1042/bj3630417 ↗
56. Assessing the sensitivity of commercially available fluorophores to the intracellular environment10.1021/ac8011347 ↗
57. Characteristics of fluoroprobes for measuring intracellular pH10.1016/0003-2697(86)90174-0 ↗
58. Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe10.1158/1078-0432.CCR-07-1958 ↗
59. Sodium-22-radiolabeled silica nanoparticles as new radiotracer for biomedical applications: in vivo positron emission tomography imaging, biodistribution, and biocompatibility10.2147/IJN.S93523 ↗
60. Redirecting transport of nanoparticle albumin-bound paclitaxel to macrophages enhances therapeutic efficacy against liver metastases10.1158/0008-5472.CAN-15-1576 ↗
61. Application of polymersomes engineered to target p32 protein for detection of small breast tumors in mice10.18632/oncotarget.24588 ↗